Several hematopoietic growth factors have been shown to affect megakaryocyte development, and two, interleukin (IL)-11 and thrombopoietin (TPO) are presently being evaluated for use in patients with thrombocytopenia. In two studies patients who required one or more platelet transfusions during their first course of chemotherapy were found to require fewer platelet transfusions if their second cycle was augmented with IL-11. The drug was generally safe, with cardiovascular compromise the only significant complication occurring in a minority of patients. Although these reports included patients with various malignancies, studies of IL-11 in patients with myeloproliferative disorders have not been presented. In several clinical trials in cancer patients treatment with TPO was safe, and when administered early following a moderately aggressive cytotoxic insult was effective in accelerating platelet recovery. In addition, in both pre-clinical and clinical trials, TPO given to stem cell donors during mobilization lead to accelerated hematopoietic recovery. Finally, TPO appears safe when administered to patients with acute myelogenous leukemia (AML), both with respect to acute toxicity and long-term outcome of the leukemia. However, when used following a 7-day course of standard chemotherapy, the agent does not appear to accelerate platelet recovery. As such, additional clinical trials to test different growth factor regimens are ongoing. A number of studies have suggested that megakaryocytic growth factors may play a role in the biology of myeloproliferative disorders. Given the potential for adversely affecting patients with these disorders, the affects of IL-11 or TPO in patients with AML must continue to be carefully studied. Leukemia (2000) 14, 505-508.
Introduction
The question of whether thrombopoietic growth factors should play a role in the supportive treatment of patients with acute leukemia or other myeloproliferative disorders will be addressed. However, it is important to first review the physiology of normal and malignant megakaryopoiesis. Basic studies of thrombopoietic growth factors suggest that these agents may play a role in myeloproliferative disorders. The use of any growth factor in a leukemic state begs the question whether the corresponding growth factor receptors have a role to play in myeloproliferative disorders. Stated in clinical terms, is it safe to give growth stimulatory agents to patients with acute leukemia?
Interleukin-11 (IL-11) and thrombopoietin (TPO), the agents that have shown the greatest promise in accelerating platelet recovery in clinical trials, play important roles in megakaryocyte development. [1] [2] [3] [4] Both agents have been shown to accelerate platelet recovery following moderately intensive chemotherapy of various malignancies. In addition, TPO has been used in patients treated for acute myelogenous leukemia (AML) and those undergoing stem cell transplantation. Although safe in both settings, the agent has been effective in accelerating hematologic recovery in transplant recipients only when given to the donors of stem cell products. With the occasional (ෂ1%) untoward effect of antibody-induced thrombocytopenia in platelet donors, the role of TPO in any of these settings must be carefully considered.
Megakaryocyte development and thrombopoietic growth factors
We are beginning to understand more about megakaryocyte development, from the hematopoietic stem cell through its intermediate stages of development, and finally to the generation of mature blood cells. Megakaryocytes undergo a series of divisions and maturation steps, starting from the myeloid stem cell, to the colony-forming unit megakaryocyte (CFU-MK), to the immature and then mature megakaryocyte, and finally fragmenting into thousands of platelets. Over the last few years a number of investigators, including some from our laboratory, have been trying to discern the relative roles of different growth factors in this process. Some growth factors, such as IL-3, are able to support the initial stages of this developmental hierarchy, but cannot promote cell differentiation beyond the stage of an immature megakaryocyte. Molecules such as thrombopoietin, however, can take primitive cells and support the entire developmental potential to megakaryocytes and platelets. Other agents, such as c-kit ligand (KL), flt3 ligand (FL), IL-6, IL-11, and leukemia inhibitory factor, have been shown to contribute to various stages of megakaryopoiesis, but only in synergy with IL-3 or TPO. For example, when added alone to bone marrow cells, even massive amounts of KL will not trigger megakaryopoiesis, while nanogram levels of the same agent, when combined with low levels of TPO, will induce exuberant production of megakaryocytes. These molecules have all been considered as potential thrombopoietic drugs. Over the past dozen years various clinical trials of these agents have been conducted. Due to a general lack of efficacy, or toxicity, molecules including KL, IL-3, and IL-6 have fallen out of favor as thrombopoietic growth factors. In contrast, two naturally occurring hematopoietic growth factors, IL-11 and TPO, have shown promise in alleviating the complications of myelosuppressive therapy.
IL-11 and TPO: physiology
IL-11 was cloned by functional expression from a bone marrow cell stromal library and reported in 1990. 1 The 23 kDa molecule is composed of 199 amino acids. It is unusual in the growth factor family in that it has no disulfide bonds and no asparagine-linked carbohydrate. The IL-11 gene localizes to human chromosome 19.
A number of investigators have shown that IL-11 acts in synergy with IL-3, KL, and FL to enhance proliferation of multiple hematopoietic cell types. Moreover, IL-11 receptors are present on a number of nonhematopoietic cell types, and the cytokine has also been shown to stimulate osteoclast growth and mucosal cells of the gastrointestinal tract. As such, there may be additional clinical roles for IL-11 in affecting the function of other organ systems. Interestingly, elimination of IL-11 function does not have a hematopoietic effect in mice. Begley and colleagues have genetically eliminated the IL-11 receptor by homologous recombination, and despite heroic efforts to find the hematopoietic phenotype, have failed to discern any effect on megakaryocytes or other blood cell lineages. 5 The second naturally occurring molecule to be tested for thrombopoietic effects is TPO. Thrombopoietin was cloned by several groups using three differing strategies. 3, [6] [7] [8] Two groups purified the protein by affinity chromatography with the TPO receptor as bait, while two different groups utilized conventional protein chromatography to obtain sufficient material to determine the amino terminal amino acid sequence. Three of these groups then used degenerate oligonucleotide probes to recover the corresponding cDNA. Alternatively, we used a novel functional expression cloning strategy 6 to obtain similar clones. The mature TPO protein contains two disulfide bonds, is 332 amino acids in length, and is extensively glycosylated, especially in the carboxyl terminal domain. The resulting molecular mass is approximately 70 kDa. The TPO gene localizes to human chromosome 3. There are several physiologic sources of TPO, including the liver and kidneys, and bone marrow stromal cells. The latter source of the hormone is particularly important in thrombocytopenic individuals.
TPO works to enhance MK maturation, stimulates the proliferation of CFU-MK, and promotes the survival of hematopoietic stem cells (HSC). TPO works in synergy with IL-3, KL, IL-11, and erythropoietin on CFU-GEMM, erythroid progenitors (BFU-E) and HSCs. 9, 10 In contrast to IL-11, genetic elimination of TPO or its receptor has a profound phenotype. The number of platelets, the number of all types of hematopoietic progenitors, and the number of HSC are all reduced to 10-20% of normal values. 11, 12 Before considering treatment of patients with AML or other myeloproliferative syndromes with TPO or IL-11, it would be desirable to know how these growth factors affect leukemic cells. As the receptors for each of these cytokines are present on hematopoietic stem cells, and on most if not all types of primitive hematopoietic progenitors, either or both of these cytokines might adversely affect leukemia cell biology. Many lines of evidence support this notion. Induced mutations of the mpl receptor are associated with myeloproliferative syndromes. Probably the best example of this is the oncogene that gave rise to the cloning of TPO. The v-mpl oncogene is a mutant form of normal TPO receptor, and causes a myeloproliferative leukemia in mice. 13 Moreover, forced expression of wild-type c-mpl can induce myeloproliferative disorders in animals, and transgenic TPO animals have a disease that very much resembles agnogenic myeloid metaplasia. 14 Additional data suggests that these molecules may play some role in naturally occurring myeloproliferative states. For example, inhibition of c-mpl expression in cultures of cells from patients with myeloproliferative disorders abrogates spontaneous hematopoietic colony formation, a characteristic feature of these disorders. 15 Moreover, the addition of either TPO or IL-11 to cultures of marrow cells from patients with acute leukemia often leads to their proliferation. 16 All of these issues raise the question of whether TPO and/or IL-11 might adversely affect the clinical outcome in patients with myeloid leukemia.
Relevant clinical data on this subject is sparse. Data from two recent studies have examined whether the expression of MPL receptor on patients with myeloproliferative disorders affects ultimate outcome. In one study, 17 the presence of the receptor on cells in patients with refractory anemia with excess blasts with or without transformation was associated with poor survival due to leukemic transformation. In contrast, a more recent study 18 examined patients with AML and found a minimal impact of the presence of the MPL receptor. In these patients treated with standard therapy, the complete remission rate was identical in the MPL positive and MPL negative subgroups. There was a reduction in duration of complete remission in the MPL positive patients however.
Despite data to suggest that the MPL receptor and TPO might play some role in the biology of leukemia, the response to TPO of these leukemic blasts in these myeloproliferative syndromes is uncertain. As alluded to above, one-half to twothirds of patients with AML display MPL receptors on the leukemic cells. Approximately one-half of the MPL bearing leukemic cells will respond to exogenous thrombopoietin. However, when cells from many of these patients begin to proliferate, they also differentiate. 16 Thus, it does not necessarily follow that the administration of this cytokine to patients with AML will be associated with an unfavorable outcome.
IL-11 and TPO: preclinical data
Preclinical studies of IL-11 in a murine model of myelosuppression were reported by Leonard and colleagues. 19 In mice subjected to radiation and chemotherapy with carboplatin, platelet recovery in a group given IL-11 was accelerated compared to controls, as was white cell and red cell production. We obtained very similar results using TPO in the same murine model. 20 We found that the platelet nadir in animals treated with various doses of TPO was not as severe as that seen in control mice, and that the platelet, erythrocyte and leukocyte counts recovered 7-14 days earlier in the TPOtreated groups.
For several reasons it was hoped that TPO might play a role in hastening engraftment following stem cell transplantation. To explore this possibility, the role of TPO following bone marrow transplantation was studied. 21 Results indicated that multiple schedules and doses of TPO failed to enhance hematopoietic recovery when administered following bone marrow transplantation. Since these initial studies were conducted, several additional pre-clinical experiments with TPO and stem cell or bone marrow transplantation have been conducted. Unfortunately, relatively unimpressive results have been reported. [22] [23] [24] However, what did become apparent was that platelet recovery and red cell recovery could be accelerated if TPO was given to the donor of the stem cell product.
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IL-11 and TPO: clinical trials
A trial conducted by Teplar and colleagues 25 looked at the effects of IL-11 on the recovery of platelet count following a modest dose of chemotherapy. The design of this study was that of secondary prophylaxis; patients who required one or more platelet transfusions during their first course of chemotherapy were then administered IL-11 during their second course of chemotherapy. Compared to placebo, where only one of 27 patients avoided platelet transfusion in the second cycle of chemotherapy, eight of 27 patients were not transfused during their second cycle of IL-11 supplemented chemotherapy. This was statistically significant and lead to the approval by the FDA for use of IL-11 in this secondary prophy-laxis setting. In clinical trials of TPO, the first published study revealed that treatment of patients undergoing chemotherapy for lung cancer with MGDF, a PEGylated, truncated form of TPO, resulted in improved platelet nadirs and accelerated recovery to baseline platelet counts. 26 However, the problem with this study as well as several early TPO trials was that the platelet nadir was not terribly severe. In two such studies, the nadirs were 60 000 and 111 000, clearly patients who would not require TPO. 26, 27 More recently, Vadhan-Raj and colleagues 28 at MD Anderson conducted a study in a more heavily treated group of patients, those with gynecologic malignancies undergoing treatment with carboplatin. This study demonstrated that compared to controls, patients receiving TPO had a less severe nadir platelet count, the number of days spent with platelets less than 50 000/l or less than 20 000/l was statistically significantly less, and the number of patients who required platelet transfusions in the cycles of chemotherapy with TPO was also reduced.
Like the preclinical trials in mice and nonhuman primates, the role of TPO in stem cell transplantation is unproven. For example, in one study reported in abstract form, the number of days for recovery to 20 000 platelets following peripheral blood stem cell transplantation was 9 days in control patients and 8.5-10.5 days in patients treated with different doses of TPO. 29 However, again reflecting what was seen in preclinical trials, administration of TPO to stem cell donors improves recovery in the transplant recipient. George Somlo and colleagues at City of Hope 30 recently reported that administration of TPO along with G-CSF during stem cell mobilization resulted in the need for far fewer apheresis procedures to collect an adequate number of CD34 + cells (4 × 10 6 /kg vs 0.8 × 10 6 /kg in the first collection), and statistically significant differences in the number of red cell transfusions (3 vs 4) and the number of platelet transfusions (4 vs 5) in patients receiving TPO during their mobilization scheme. If this result can be confirmed, it suggests that TPO may play a role in the donation phase of stem cell transplantation.
Finally, to return to the initial question of whether thrombopoietic growth factors may play a supportive role in the treatment of patients with acute leukemia, thus far the answer does not appear promising, at least administering the drug once all chemotherapy is completed. There has been one trial published in abstract form using TPO in patients undergoing conventional chemotherapy for AML. 31 This study showed that despite having a greater overshoot in the platelet count during the post-chemotherapy recovery phase, the day that the platelet count rose above 20 000 was no different in the group of patients receiving either dose of TPO than in the placebo control group, and the number of platelet transfusions was identical in the TPO-treated and control patients.
One of the potential problems with the approach to supportive therapy taken thus far is that of delayed administration of TPO. A number of investigators have found that the timing of TPO administration following a myelosuppressive insult is critical for its effect on hematopoietic recovery. Waiting as little as 24-48 h following the initial onset of cytotoxic therapy will blunt or abrogate the favorable effects of TPO on hematopoietic recovery. 32 Hence, as chemotherapy is administered over 7 days to the patients with AML, it is entirely possible that delay of TPO therapy until day 8 was responsible for the lack of favorable effects. Only carefully controlled and welldesigned clinical trials will be able to address this issue.
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Conclusions
In conclusion, IL-11 is well tolerated with the exception of fluid overload in some patients. It has been found to improve platelet recovery in cancer patients undergoing conventional chemotherapy, and it has been approved by the FDA in a secondary prophylaxis setting. TPO has been proven safe in cancer patients, including those with AML, and effective in certain clinical settings, although thrombocytopenia has developed in about 1% of normal platelet donors subcutaneously administered at least two or three doses of the drug. The use of TPO in stem cell mobilization regimens shows promise in reducing the number of apheresis procedures required, and accelerating hematopoietic recovery in the recipients of the transplanted products. Clearly, further clinical trials are necessary to establish the multiple roles of IL-11 and TPO in therapy of patients with acute leukemia and other forms of cancer.
